Drug Trial Radar · NCT01417091
Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta
Last checked: Nov 19, 2026Latest source record: May 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jun 2011
Primary completion
Dec 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 16, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open label intra-patient dose escalation study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of BPS804 in adults with osteogenesis imperfecta (OI). Pharmacodynamic effect will be determined by serological biomarkers and radiologic assessments. In addition, tolerability and pharmacokinetics (PK) will be evaluated.
Conditions
- Osteogenesis Imperfecta
Interventions
BPS804Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability (composite outcome: standard laboratory, (serious) adverse events)Time frame: Day 1 through 141
- Determination of pharmacodynamic effect by means of biomarkersTime frame: Day 1 and Day 43
- Change in Z-score from baseline to Day 141Time frame: Day 1 and Day 141
Locations
6 sites in 4 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Anaheim, California
Novartis Investigative Site
Miramar, Florida
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Würzburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.